171 related articles for article (PubMed ID: 30878952)
1. Lanthanum phosphate binder-induced iron deficiency anaemia.
Awad C; Gilkison K; Shaw E
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30878952
[TBL] [Abstract][Full Text] [Related]
2. Lanthanum deposition from oral lanthanum carbonate in the upper gastrointestinal tract.
Hoda RS; Sanyal S; Abraham JL; Everett JM; Hundemer GL; Yee E; Lauwers GY; Tolkoff-Rubin N; Misdraji J
Histopathology; 2017 Jun; 70(7):1072-1078. PubMed ID: 28134986
[TBL] [Abstract][Full Text] [Related]
3. [Radiographic characteristics of lanthanum carbonate absorption].
Vrigneaud L; Lefèbvre D; Daem AO; Lemaitre V
Nephrol Ther; 2008 Apr; 4(2):111-3. PubMed ID: 18243834
[TBL] [Abstract][Full Text] [Related]
4. Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study.
Vemuri N; Michelis MF; Matalon A
BMC Nephrol; 2011 Sep; 12():49. PubMed ID: 21962172
[TBL] [Abstract][Full Text] [Related]
5. [Deposits of lanthanum in the gastric mucosa of a patient with chronic kidney disease].
António da Conceiçao A; Chiva Robles MT; Porres Cubero JC; Saus Sarrias C; Castellano Megías VM
Rev Esp Patol; 2019; 52(2):112-116. PubMed ID: 30902374
[TBL] [Abstract][Full Text] [Related]
6. Review of the diagnosis of gastrointestinal lanthanum deposition.
Iwamuro M; Urata H; Tanaka T; Okada H
World J Gastroenterol; 2020 Apr; 26(13):1439-1449. PubMed ID: 32308345
[TBL] [Abstract][Full Text] [Related]
7. Clinical usefulness of lanthanum carbonate for serum phosphate control in difficult patients.
Almirall J; Betancourt L; Esteve V; Valenzuela MP; López T; Ruiz A; Martínez-Ocaña JC; Calvet X
Int Urol Nephrol; 2012 Feb; 44(1):231-6. PubMed ID: 21069570
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
Shigematsu T; Ohya M; Negi S; Masumoto AR; Nakashima YM; Iwatani Y; Moribata MK; Yamanaka S; Tatsuta K; Mima T
Contrib Nephrol; 2015; 185():42-55. PubMed ID: 26023014
[TBL] [Abstract][Full Text] [Related]
9. Lanthanum carbonate: safety data after 10 years.
Hutchison AJ; Wilson RJ; Garafola S; Copley JB
Nephrology (Carlton); 2016 Dec; 21(12):987-994. PubMed ID: 27479781
[TBL] [Abstract][Full Text] [Related]
10. Lanthanum deposition in the gastrointestinal mucosa and regional lymph nodes in dialysis patients: Analysis of surgically excised specimens and review of the literature.
Yabuki K; Shiba E; Harada H; Uchihashi K; Matsuyama A; Haratake J; Hisaoka M
Pathol Res Pract; 2016 Oct; 212(10):919-926. PubMed ID: 27515549
[TBL] [Abstract][Full Text] [Related]
11. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
Shigematsu T;
Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
[TBL] [Abstract][Full Text] [Related]
12. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
Negi S; Shigematsu T
Clin Calcium; 2010 Jul; 20(7):1096-102. PubMed ID: 20585189
[TBL] [Abstract][Full Text] [Related]
13. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.
Damment SJ; Pennick M
Clin Pharmacokinet; 2008; 47(9):553-63. PubMed ID: 18698878
[TBL] [Abstract][Full Text] [Related]
15. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
Shigematsu T;
Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
[TBL] [Abstract][Full Text] [Related]
16. Real-world dose-relativity, tablet burden, and cost comparison of conversion between sevelamer hydrochloride/carbonate and lanthanum carbonate monotherapies.
Keith MS; Sibbel S; Copley JB; Wilson RJ; Brunelli SM
Clin Ther; 2014 Oct; 36(10):1431-42.e1. PubMed ID: 25150194
[TBL] [Abstract][Full Text] [Related]
17. [Is lanthanum carbonate a safe drug?].
Kazama JJ
Clin Calcium; 2009 Feb; 19(2):224-8. PubMed ID: 19182363
[TBL] [Abstract][Full Text] [Related]
18. [Iron-based Phosphate Binders for ESRD Patients].
Cozzolino M; Mangano M; Magagnoli L; Di Lullo L; Galassi A; Brancaccio D; Bellasi A
G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545638
[TBL] [Abstract][Full Text] [Related]
19. A 47-Year-Old Man with Hyperphosphatemia Due to Chronic Renal Failure Treated with Lanthanum Carbonate Tablets Presenting Acutely with Partial Large Bowel Obstruction.
Zhou Q; Yu M; Chang X; Shang S; Li M; Xu W
Am J Case Rep; 2023 Nov; 24():e942113. PubMed ID: 37994013
[TBL] [Abstract][Full Text] [Related]
20. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
Lee YK; Choi HY; Shin SK; Lee HY
Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
